Effective policy initiatives to constrain lipid-lowering drug expenditure growth in South Korea

BMC Health Services Research

Volumn 14, Issue , 2014, Pages

  Bae, Green ^a,b   Park, Chanmi ^a   Lee, Hyejin ^a   Han, Euna ^c   Kim, Dong Sook ^a   Jang, Sunmee ^d  

^a Health Insurance Review & Assessment Service Korea   (South Korea)

^b Ewha Womans University   (South Korea)

^c Yonsei University   (South Korea)

^d Gachon University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

COST CONTROL; DRUG COST; ECONOMIC MODEL; ECONOMICS; HEALTH CARE POLICY; HUMAN; INSURANCE; ORGANIZATION AND MANAGEMENT; PROCEDURES; PUBLIC HEALTH; SOUTH KOREA; STATISTICS AND NUMERICAL DATA;

COST CONTROL; DRUG COSTS; HEALTH POLICY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOLIPIDEMIC AGENTS; INSURANCE CLAIM REVIEW; MODELS, ECONOMIC; NATIONAL HEALTH PROGRAMS; REPUBLIC OF KOREA;

EID: 84898833602     PISSN: None     EISSN: 14726963     Source Type: Journal    
DOI: 10.1186/1472-6963-14-100     Document Type: Article

References (27)

1. Assessment HIRA CN, Health Insurance Statistics, 2001-2010 Korea: HIRA health insurance review & assessment 2012
2. Evaluation on the first 2 years of the positive list system in South Korea. Park SE, Lim SH, Choi HW, Lee SM, Kim DW, Yim EY, Kim KH, Yi SY, Health Policy 2012 104 1 32 39 10.1016/j.healthpol.2011.09.006 22001369
3. Drug re-evaluation system, health technology assessment, cost-effectiveness, social value. Bae EY, Korean J Health Econ Policy 2010 16 3 163 187
4. Price cuts and drug spending in South Korea: The case of antihyperlipidemic agents. Kwon H-Y, Hong J-M, Godman B, Yang B-M, Health Policy 2013 112 3 217 226 10.1016/j.healthpol.2013.08.011 24075008
5. The New EMCDDA Standard Table on Public Expenditure: a step forward in quantifying drug-related costs in Europe. Prieto L, Flöter S, Suchttherapie 2009 10 S 01 211
6. Decomposing pharmaceutical cost growth in different types of health plans. Chernew M, Smith D, Kirking D, Fendrick A, Am J Manag Care 2001 7 7 667 11464425
7. Statistics for drug consumption http://kosis.kr/statHtml/statHtml.do? orgId=117&tblId=DT-11781-N002&vw-cd=&list-id=&seqNo= &lang-mode=ko&obj-var-id=&itm-id=&conn-path#
8. DDD Index http://www.whocc.no/atc-ddd-index/
9. WHO Collaborating Centre for Drug Statistics Methodology, Guidelines for ATC classification and DDD assignment, 2011 Oslo 2010 http://www.scribd.com/doc/ 24257045/ATC-2010-Guidelines
10. Definition and general considerations http://www.whocc.no/ddd/definition- and-general-considera/
11. Ministry of Security and Public Administration, Consumer Price Index (CPI) Municipal Year Book of Korea, Statistics Korea 2009 http://www.index.go. kr/potal/stts/idxMain/selectPoSttsIdxSearch.do?idx-cd=1060&clas-div= &idx-sys-cd=530&idx-clas-cd=1
12. Exchange rate. 2001-2011 The Bank of Korea 2013 http://ecos.bok.or.kr/
13. Korea Centers for Disease Control and Prevention (KCDC), Korea Health & Nutrition Examination Survey: KHNES 2011 http://www.google.co.kr/url?sa= t&rct=j&q=&esrc=s&frm=1&source=web&cd=2&ved= 0CDwQFjAB&url=http%3A%2F%2Fwww.index.go.kr%2Fcom%2Fcmm%2Ffms%2FFileDown. do%3Bjsessionid%3DZ1q6VZoa1fygQ9Ip1QBs40vf9q9t8qV1vT0arNE9GmdzzP2e22KvlOnebvvCi 2m1.wasgams1-servlet-engine1%3Fapnd-file-id%3D2765%26apnd-file-seq%3D2&ei= WU8mU83mLM6UkgWX-oGoCQ&usg=AFQjCNFRIk2sQ77moy57eeAIcE0NFsyKxQ&sig2= aMxwIn2aROjXk29MzPuaYQ&bvm=bv.62922401,d.dGI&cad=rjt
14. Cardiovascular disease: different strategies for primary and secondary prevention? Hobbs F, Heart 2004 90 10 1217 1223 10.1136/hrt.2003.027680 15367530
15. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, Dallongeville J, De Backer G, Ebrahim S, Gjelsvik B, Herrmann-Lingen C, Hoes A, Humphries S, Knapton M, Perk J, Priori SG, Pyorala K, Reiner Z, Ruilope L, Sans-Menendez S, Op Reimer WS, Weissberg P, Wood D, Yarnell J, Zamorano JL, Walma E, Fitzgerald T, Cooney MT, Dudina A, Vahanian A, et al. Eur J Cardiovasc Prev Rehabil 2007 14 Suppl 2 1 113
16. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, Dallongeville J, De Backer G, Ebrahim S, Gjelsvik B, Herrmann-Lingen C, Hoes A, Humphries S, Knapton M, Perk J, Priori SG, Pyorala K, Reiner Z, Ruilope L, Sans-Menendez S, Op Reimer WS, Weissberg P, Wood D, Yarnell J, Zamorano JL, Walma E, Fitzgerald T, Cooney MT, Dudina A, Vahanian A, et al. Eur J Cardiovasc Prev Rehabil 2007 14 Suppl 2 1 40 17726406
17. Risk factors of atherosclerotic diseases. Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerosis cardiovascular diseases for Japanese. Teramoto T, Sasaki J, Ueshima H, Egusa G, Kinoshita M, Shimamoto K, Daida H, Biro S, Hirobe K, Funahashi T, Yokote K, Yokode M, J Atheroscler Thromb 2007 14 6 267 277 10.5551/jat.E578 18176013
18. Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese. Teramoto T, Sasaki J, Ueshima H, Egusa G, Kinoshita M, Shimamoto K, Daida H, Biro S, Hirobe K, Funahashi T, Yokote K, Yokode M, J Atheroscler Thromb 2007 14 2 45 50 10.5551/jat.14.45 17485887
19. Statin therapy and risks for death and hospitalization in chronic heart failure. Go AS, Lee WY, Yang J, Lo JC, Gurwitz JH, JAMA: J Am Med Assoc 2006 296 17 2105 2111 10.1001/jama.296.17.2105
20. Major growths of Korean pharmaceutical expenditure. Choi Y-J, Shalowitz JI, J Korea Soc Health Informatics Stat 2011 36 1 15 24
21. Study on the drug expenditure trend in Korea. Bae E-Y, Korean J Health Econ Policy 2007 13 2 39 54
22. Analysis of determinants of inpatient pharmaceutical expenditure in NHI. Jang S, Park C, Choi Y-J, Bae G, Korean J Health Econ Policy 2010 16 3 115 137
23. Policies to enhance prescribing efficiency in Europe: findings and future implications. Godman B, Shrank W, Andersen M, Berg C, Bishop I, Burkhardt T, Garuoliene K, Herholz H, Joppi R, Kalaba M, Front Pharmacol 2010 1
24. Paris V, Docteur E, Pharmaceutical pricing and reimbursement policies in Germany OECD 2008
25. Sustaining generic medicines markets in Europe. Simoens S, De Coster S, J Generic Med 2006 3 4 257 268 10.1057/palgrave.jgm.4940128
26. Guidelines for ATC classification and DDD assignment, 2014. WHO Collaborating Centre for Drug Statistics Methodology, Oslo 2013 http://www.whocc.no/filearchive/publications/1-2013guidelines.pdf
27. New drugs and the growth of health expenditure: evidence from diabetic patients in Taiwan. Liu YM, Hsieh CR, Health Econ 2012 21 5 496 513 10.1002/hec.1724 21394819